Recently, the 20th National Symposium on Ophthalmic Refractive Surgery (CSORS) 2025 successfully concluded in Kunming. At the "Special Session on Clinical Progress of Domestic Innovative Femtosecond FINE", participants and hosts focused on Xianwei Vision's innovative exploration and latest clinical research progress in domestic innovative femtosecond FINE, conducting in-depth exchanges with numerous experts and elites in the refractive field on-site and online to jointly explore the future of domestic innovative femtosecond technology.

During the special session, Professor Zhou Xingtao from Eye, Ear, Nose and Throat Hospital of Fudan University mentioned that Xianwei Vision's FineVision 2000 device currently requires only 8.80 seconds of laser scanning time for the KLEx procedure and merely 4.92 seconds for the Flap procedure. Xianwei's R&D team, with an indomitable spirit of research, has elevated the parametric indicators of femtosecond lasers to a new level, making surgeries safer. Professor Wang Yan from Tianjin Eye Hospital Affiliated to Nankai University pointed out that Xianwei Vision's R&D team organically integrates scientific research with clinical practice. With a rigorous research attitude and steady progress, they have proposed "fast, safe and precise" solutions to the pain points in clinical applications, and their achievements have been highly recognized by experts at numerous national ophthalmology conferences. Professor Shaoqun Zeng from Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, introduced a method jointly developed by Xianwei's clinical research team, which can measure appropriate mechanical parameters in vivo to further optimize the cutting parameters of KLEx and Flap procedures.

In December 2022, Nanjing Innovation Investment Group participated in Xianwei Vision's angel round financing. In January 2025, Xianwei Vision completed a subsequent round of financing exceeding RMB 100 million led by Lilly Asia Ventures, with Nanjing Innovation Investment Group continuing to increase its investment to support the enterprise in further exploring pre-clinical applications of femtosecond devices. Yan Peng'an, General Manager of the Third Investment Department of Nanjing Innovation Investment Group, said: "We sincerely congratulate Xianwei Vision and its core team on successfully completing the first domestic clinical enrollment of all-femtosecond laser refractive surgery equipment! This breakthrough achievement is a landmark milestone in the field of high-end domestic ophthalmic medical devices. As an investor, we are honored to walk alongside the top team led by Professor Shaoqun Zeng and General Manager Cao, witnessing them promote the clinical implementation of large domestic ophthalmic devices with core technologies. This not only successfully breaks the long-term monopoly of Western countries in the field of femtosecond laser ophthalmic surgical instruments, but also significantly improves the level of personalized treatment and clinical application of domestic femtosecond refractive surgery, injecting strong momentum into the high-end and independent development of domestic medical devices, and making important contributions to the high-quality development of China's ophthalmic medical and health undertakings."